Reports
Sale
Preeclampsia Market Size, Share, Analysis, Trends, Forecast: By Treatment: Medication to Lower B.P., Corticosteroids, Anticonvulsants Medication; By Disease Type: Mild Preeclampsia, Severe Preeclampsia; By End User: Hospitals, Clinics, Others; Regional Analysis; Market Dynamics; Patent Analysis; Grants Analysis; Supplier Landscape; 2024-2032
Preeclampsia Market Outlook
The preeclampsia market size is expected to grow at a CAGR of 1.8% during the forecast period of 2024-2032, driven by the increasing incidence of pregnancies, along with growing hypertension prevalence across major markets.
Preeclampsia Market Overview
Preeclampsia is a pregnancy complication wherein the mother may have high blood pressure, and elevated protein levels in the urine indicating kidney damage or organ damage. It is one of the most documented gestational complications, affecting around 2-15% of all pregnant women. In 2023, the worldwide incidence of the condition is around 7 million. It is the main cause of 17% maternal deaths and 15% premature births.
The preeclampsia market demand is primarily driven by the increasing incidence of gestational and chronic hypertension in women. It begins after 20 weeks of pregnancy. Symptoms may include decreased levels of platelets in the blood, increased levels of liver enzymes, changes in vision and severe headaches among others. If left untreated, it may lead to fatal complications for the foetus as well as the mother. Consequently, there has been a high focus on developing effective therapeutics as well as diagnostics to alleviate the risks and morbidities associated with the disease.
Intensive Research Activities to Drive the Preeclampsia Market Growth
In September 2023, researchers at Brown University and Western University revealed in a study that the cis P-tau protein, which is commonly associated with neurological diseases such as stroke and Alzheimer’s disease, may also be a biomarker for preeclampsia. This indicates the trend of intensive research to develop better and improved treatment alternatives for patients.
Development in Diagnostic Tools to Provide Early and Appropriate Treatment
In May 2023, Thermo Fisher Scientific received the FDA clearance for two assays, designed to assess the risk of developing preeclampsia in pregnant women. The Placental Growth Factor (PlGF) plus and soluble FMS-like tyrosine kinase-1 receptor (sFlt-1) assays can be used with other lab tests and clinical assessments to evaluate if pregnant hospitalised women are at the verge of developing the complication or not. It is run on the BRAHMS KRYPTOR chemistry analyser for 30 minutes and has been validated on basis of its successful examination on more than 700 pregnant women in 18 hospitals. The rising application and installation of such technologies in hospitals and clinics is expected to increase the preeclampsia market share in upcoming years.
Adding to the preexisting research, the scientists from KU Leuven unveiled that a DNA analysis, which may be done alongside NIPT test (used to detect chromosomal abnormalities in the foetus) can help analyse which women are at the higher risk of preeclampsia in the late stages of their pregnancy.
Expediated Drug Development and Growth in Drug Approvals
In August 2023, Comanche Biopharma Corp. received FDA’s Fast Track Designation for their investigational drug called CBP-4888 for the treatment of sFlt1-mediated pre-term preeclampsia. Based on siRNA therapeutic and delivered subcutaneously, the drug is currently under phase 1 clinical rials. This investigational therapy is expected to offer significant advantage over preexisting treatment alternatives for preeclampsia.
The preeclampsia market value is further fuelled by the growing application of antihypertensive drugs for the treatment. Methyldopa is one of the most common drugs used to treat the condition. Hydralazine and Nifedipine are also frequently used. Statins are amongst the common therapies being used for prevention and treatment. Owing to technical advancements and a better understanding of genetics, the treatment market is expected to grow exponentially in the upcoming years.
Preeclampsia Market Segmentation
Market Breakup by Treatment
- Medication to Lower B.P.
- Corticosteroids
- Anticonvulsants Medication
Market Breakup by Disease Type
- Mild Preeclampsia
- Severe Preeclampsia
Market Breakup by End User
- Hospitals
- Clinics
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Preeclampsia Market Regional Analysis
The United States is projected to dominate the preeclampsia market share in the forecast period. The market value can be attributed to imparting significant focus on decreasing neonatal mortality rates due to premature delivery. With a well-equipped healthcare infrastructure, the government along with the key healthcare companies play a critical role in spreading awareness around early diagnosis of the condition. The rising prevalence of telehealth has bolstered market growth as patients adopt such solutions for immediate consultations.
Europe is a major market for preeclampsia treatment, offering innovative treatment options with the help of novel technologies. The presence of various academic institutions and research centers helps with market growth. Moreover, the increasing number of collaborative projects between universities and pharmaceutical companies is also helping the growth.
In Asia Pacific, Japan holds a substantial share of the market value. Yet, India and China, are projected to witness high preeclampsia market growth. This is because the regions are witnessing significantly more pregnancies than others, increasing the disease prevalence rate. In addition, there is a heightened focus on improving the healthcare infrastructure and developing better therapeutic strategies for the patients.
Preeclampsia Market: Competitor Landscape
In March 2023, Northwell Health and Aegis Ventures' company Ascertain revealed their collaboration aimed at using machine learning technologies to predict preeclampsia. The venture is aimed at reducing maternal mortality rates with new age techniques such as artificial intelligence. The proprietary algorithm displayed a 10- to 15-times increase over the current predictive standard detection, making it a promising methodology of analysis in the forthcoming years.
The key features of the preeclampsia market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Thermo Fisher Scientific Inc.
- Baxter
- Bayer AG
- Merck & Co., Inc
- F. Hoffmann-La Roche Ltd
- Siemens Healthcare GmbH
- PerkinElmer Inc
- Sera Prognostics
- DRG Instruments GMBH
- Metabolomic Diagnostics
- Diabetomics, Inc.
- Hitachi Ltd
- Cardinal Health Inc
- BioMerieux SA
- Fujirebio Diagnostics
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment |
|
| Breakup by Disease Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Preeclampsia Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Preeclampsia Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Preeclampsia Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Preeclampsia Epidemiology Forecast (2017-2032)
5.3.1 Germany Preeclampsia Epidemiology Forecast (2017-2032)
5.3.2 France Preeclampsia Epidemiology Forecast (2017-2032)
5.3.3 Italy Preeclampsia Epidemiology Forecast (2017-2032)
5.3.4 Spain Preeclampsia Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Preeclampsia Epidemiology Forecast (2017-2032)
5.4 Japan Preeclampsia Epidemiology Forecast (2017-2032)
6 Preeclampsia Market Overview – 7MM
6.1 Preeclampsia Market Historical Value (2017-2023)
6.2 Preeclampsia Market Forecast Value (2024-2032)
7 Preeclampsia Market Landscape – 7MM
7.1 Preeclampsia Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Preeclampsia Product Landscape
7.2.1 Analysis by Products
7.2.2 Analysis by Indications
7.2.3 Analysis by Route of Administration
8 Preeclampsia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Preeclampsia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Preeclampsia Market Segmentation – 7MM
11.1 Preeclampsia Market by Treatment
11.1.1 Market Overview
11.1.2 Medication to Lower B.P.
11.1.3 Corticosteroids
11.1.4 Anticonvulsants Medication
11.2 Preeclampsia Market by Disease Type
11.2.1 Market Overview
11.2.2 Mild Preeclampsia
11.2.3 Severe Preeclampsia
11.3 Preeclampsia Market by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Clinics
11.3.4 Others
11.4 Preeclampsia Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
12 United States Preeclampsia Market
12.1 Preeclampsia Market Historical Value (2017-2023)
12.2 Preeclampsia Market Forecast Value (2024-2032)
12.3 Preeclampsia Market by Disease Type
12.4 Preeclampsia Market by Treatment Type
13 EU-4 and United Kingdom Preeclampsia Market
13.1 Preeclampsia Market Historical Value (2017-2023)
13.2 Preeclampsia Market Forecast Value (2024-2032)
13.3 Germany Preeclampsia Market Overview
13.3.1 Preeclampsia Market by Disease Type
13.3.2 Preeclampsia Market by Treatment Type
13.4 France Preeclampsia Market Overview
13.4.1 Preeclampsia Market by Disease Type
13.4.2 Preeclampsia Market by Treatment Type
13.5 Italy Preeclampsia Market Overview
13.5.1 Preeclampsia Market by Disease Type
13.5.2 Preeclampsia Market by Treatment Type
13.6 Spain Preeclampsia Market Overview
13.6.1 Preeclampsia Market by Disease Type
13.6.2 Preeclampsia Market by Treatment Type
13.7 United Kingdom Preeclampsia Market Overview
13.7.1 Preeclampsia Market by Disease Type
13.7.2 Preeclampsia Market by Treatment Type
14 Japan Preeclampsia Market
14.1 Preeclampsia Market Historical Value (2017-2023)
14.2 Preeclampsia Market Forecast Value (2024-2032)
14.2.1 Preeclampsia Market by Disease Type
14.2.2 Preeclampsia Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Thermo Fisher Scientific Inc.
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Baxter
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Bayer AG
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Merck & Co., Inc
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 F. Hoffmann-La Roche Ltd
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Siemens Healthcare GmbH
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 PerkinElmer Inc
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Sera Prognostics
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 DRG Instruments GMBH
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Metabolomic Diagnostics
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Diabetomics, Inc.
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Hitachi Ltd
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Cardinal Health Inc
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 BioMerieux SA
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 Fujirebio Diagnostics
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Preeclampsia Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 1.8% during the forecast period of 2024-2032, likely to be driven by the growing incidence of pregnancies along with increasing hypertension prevalence across major markets.
The market demand is majorly driven by the increasing incidence of hypertension in women owing to increased stressful, sedentary lifestyle and unhealthy dietary habits.
The current market trend revolves around high emphasis on early diagnosis of the disease for improved treatment alternatives. In September 2023, the researchers at Brown University and Western University conducted a study to reveal that the cis P-tau protein, which is commonly associated with neurological diseases such as stroke and Alzheimer’s disease may also be a biomarker for preeclampsia.
Based on treatment types, the market is divided into medication to lower B.P., corticosteroids and anticonvulsants medication.
The market is divided into mild and severe preeclampsia.
Major end users include hospitals, clinics, and others.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Thermo Fisher Scientific Inc., Baxter, Bayer AG, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, PerkinElmer Inc., Sera Prognostics, DRG Instruments GMBH, Metabolomic Diagnostics, Diabetomics, Inc., Hitachi Ltd., Cardinal Health Inc., BioMerieux SA and Fujirebio Diagnostics.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER